Ocular Therapeutix Inc (OCUL) Stock AnalysisOCULStock AnalysisOcular Therapeutix Inc

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ocular Therapeutix Inc (OCUL) appears to be a good buy right now due to its recent positive trial results and bullish analyst ratings. The stock is currently priced at $10.36, with analysts setting price targets as high as $30, suggesting a potential upside of over 189%. Additionally, the RSI is at 41.34, indicating that the stock is not overbought, and the recent surge in market sentiment following EyePoint's trial failure strengthens OCUL's competitive position. However, the company has reported substantial net losses, with a net income of -78.76 million in Q2 2026, which remains a significant risk to consider.

7 analysts cover OCUL: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 23.43.